Beryllium toxicity

Beryllium toxicity encompasses two distinct pulmonary diseases caused by exposure to beryllium metal, alloys, or compounds: acute beryllium disease (ABD), a chemical pneumonitis from high-dose inhalation, and chronic beryllium disease (CBD, berylliosis), a cell-mediated granulomatous lung disease that is clinically, radiographically, and histopathologically indistinguishable from sarcoidosis. ABD is now rare due to workplace exposure limits. CBD remains an active occupational health concern. Beryllium is classified as a Group 1 carcinogen (lung cancer) by IARC. The ED physician's key role is to consider beryllium exposure in any patient diagnosed with "sarcoidosis" who has occupational exposure, and to manage acute inhalational injury.

Background

• Beryllium is a lightweight metal used in aerospace, defense, nuclear weapons, electronics, telecommunications, dental alloys, high-technology ceramics, metal recycling, and automotive manufacturing
• Estimated 134,000 workers in the United States are exposed to beryllium
• Two distinct diseases:
  • Acute beryllium disease (ABD): Direct chemical/toxic pneumonitis from high-dose inhalation; dose-dependent; now rare due to exposure controls; onset within hours to days of heavy exposure; most patients recover with removal from exposure
  • Chronic beryllium disease (CBD): Cell-mediated (type IV) hypersensitivity reaction; requires prior sensitization; not dose-dependent — can occur even at levels below OSHA PEL; latency period 3 months to 30+ years from initial exposure
• Pathogenesis of CBD:
  • Beryllium acts as a hapten → presented by MHC class II (especially HLA-DPB1 Glu69) to CD4+ T cells → T-cell sensitization → upon re-exposure, proliferation of beryllium-specific CD4+ T cells → release of TNF-α, IL-2, IFN-γ → noncaseating granuloma formation
  • Essentially identical pathogenesis to sarcoidosis (granulomatous inflammation driven by CD4+ T-cell response to an antigen)
• Beryllium sensitization (BeS): Immune sensitization without clinical disease; detected by beryllium lymphocyte proliferation test (BeLPT); 2–6% of exposed workers become sensitized; among sensitized workers, ~66% progress to CBD
• Skin exposure (not just inhalation) may cause sensitization
• Chelation therapy is ineffective — beryllium is poorly soluble and persists in the body for the individual's lifetime
• OSHA permissible exposure limit: 0.2 µg/m³ (8-hour TWA); cases still occur below this threshold

Clinical Features

Acute beryllium disease (rare):

• Onset hours to days after heavy inhalation exposure
• Severe cough, dyspnea, chest tightness
• Chemical pneumonitis → pulmonary edema → ARDS in severe cases
• Rhinitis, pharyngitis, tracheobronchitis with upper airway irritation
• May be fulminant and fatal if exposure is massive
• Most patients recover over weeks to months if removed from exposure, though may recur with re-exposure

Chronic beryllium disease:

• Insidious onset — latency period of months to decades (mean ~10 years) after initial exposure
• Progressive dyspnea on exertion (most common symptom)
• Persistent dry cough
• Fatigue, weight loss
• Fever, night sweats (mimics tuberculosis or lymphoma)
• Chest pain (uncommon)
• Physical exam:
  • May be normal early in disease (many cases detected by surveillance BeLPT before symptoms develop)
  • Bibasal inspiratory crackles
  • Lymphadenopathy
  • Hepatosplenomegaly (rare)
• Extrapulmonary manifestations (less common than sarcoidosis):
  • Skin: Granulomatous skin lesions — most common extrapulmonary manifestation; contact dermatitis; subcutaneous nodules at sites of skin implantation (embedded beryllium particles)
  • Granulomatous hepatitis
  • Hypercalcemia
  • Nephrolithiasis (kidney stones)
  • Uveitis (less common than in sarcoidosis)

Beryllium dermatitis:

• Contact dermatitis from skin exposure to beryllium salts
• Patients who develop beryllium contact dermatitis are at high risk for beryllium sensitization and subsequent CBD

Differential Diagnosis

• Sarcoidosis — the most important differential; clinically indistinguishable from CBD; any patient diagnosed with "sarcoidosis" who has a history of beryllium exposure should be evaluated for CBD with BeLPT
• Tuberculosis (caseating granulomas; AFB stain/culture positive; unlike CBD which has noncaseating granulomas)
• Hypersensitivity pneumonitis (exposure history differs; bronchiolocentric poorly formed granulomas vs. well-formed granulomas of CBD)
• Other pneumoconioses (silicosis, asbestosis)
• Idiopathic pulmonary fibrosis
• Fungal infections (histoplasmosis, coccidioidomycosis — also cause granulomas)
• Lymphoma (hilar lymphadenopathy, constitutional symptoms)
• Lung cancer (beryllium is a Group 1 carcinogen; may coexist with CBD)
• For acute beryllium disease:
  • Toxic inhalation injury (chlorine, phosgene, metal fume fever)
  • Acute eosinophilic pneumonia
  • Pneumonia
  • ARDS from other causes

Evaluation

Workup

History — the most critical diagnostic tool:

• Detailed occupational history: Current and all prior employment; specifically ask about aerospace, defense, nuclear, electronics, telecommunications, dental laboratory, ceramics, metal alloy machining, metal recycling, and jewelry work
• Do not rely on the patient knowing they were exposed — many workers are unaware that beryllium is present in their workplace (copper-beryllium alloys, aluminum-beryllium alloys are common); even clerical workers in beryllium facilities have developed sensitization
• Duration and intensity of exposure (though CBD can occur at very low levels)
• Household/bystander exposure (contaminated work clothing brought home)
• Latency period may be very long — ask about exposures decades ago

Laboratory (ED):

• CBC, CMP (renal function, calcium)
• Serum calcium: Hypercalcemia may occur (granulomatous production of 1,25-dihydroxyvitamin D, as in sarcoidosis)
• ACE level: Often elevated (same mechanism as sarcoidosis; nonspecific)
• ABG/VBG: Hypoxemia, especially with exercise
• ESR/CRP: May be elevated
• Beryllium lymphocyte proliferation test (BeLPT): NOT an ED test — requires specialized laboratory; performed on peripheral blood or BAL fluid; detects beryllium-specific T-cell sensitization; forms the basis of diagnosis
  • Two abnormal blood BeLPTs or one abnormal BAL BeLPT confirms beryllium sensitization
  • Sensitivity ~75–90% for blood BeLPT; BAL BeLPT is more sensitive
• Note: There are no useful serum or urine beryllium levels for clinical diagnosis — body burden is not reflected by blood/urine concentrations, and beryllium is poorly soluble

Imaging:

Chest X-ray:

• May be normal early in CBD
• Abnormalities often indistinguishable from sarcoidosis:
  • Bilateral hilar and mediastinal lymphadenopathy
  • Diffuse reticulonodular infiltrates
  • Upper-lobe predominance of parenchymal opacities
• Acute beryllium disease: diffuse bilateral hazy/ground-glass opacities → frank pulmonary edema pattern

HRCT (more sensitive than CXR):

• Ground-glass opacities
• Small parenchymal nodules (along bronchovascular bundles and subpleural — identical to sarcoidosis)
• Mediastinal and hilar lymphadenopathy
• Fibrosis, honeycombing in advanced disease
• May be normal in early CBD

Pulmonary function tests (outpatient):

• Restrictive pattern most common (reduced FVC, reduced TLC)
• Reduced DLCO (often the earliest PFT abnormality)
• May show obstructive or mixed pattern
• Exercise-induced desaturation (useful for detecting early disease)

Diagnosis

• Definitive diagnosis of CBD requires:
  • (1) History of beryllium exposure
  • (2) Positive BeLPT (beryllium sensitization confirmed)
  • (3) Granulomatous inflammation on lung biopsy
• Probable CBD can be diagnosed with two of these three criteria when the third is unavailable
• In the ED: Definitive diagnosis is not possible — the key is to consider the diagnosis in any patient presenting with a sarcoidosis-like picture who has occupational beryllium exposure history
• Any patient diagnosed with sarcoidosis who has any history of beryllium exposure should be referred for BeLPT testing to rule out CBD
• Lung biopsy (transbronchial or surgical) shows noncaseating granulomas identical to sarcoidosis; special stains and cultures are negative for mycobacteria and fungi
• BAL typically shows lymphocytosis with increased CD4:CD8 ratio (similar to sarcoidosis)

Management

Acute beryllium disease (chemical pneumonitis):

• Remove from exposure immediately
• Supplemental O2; high-flow or non-invasive ventilation as needed
• Intubation and mechanical ventilation for ARDS
• Systemic corticosteroids (methylprednisolone IV or prednisone PO) for significant pulmonary inflammation
• Bronchodilators for bronchospasm
• Standard ARDS management if severe (low tidal volume ventilation, prone positioning)
• Supportive care: IV fluids, monitoring
• Skin decontamination if dermal exposure (copious water irrigation; embedded beryllium particles may require surgical excision to prevent chronic granulomatous skin lesions)
• Chelation therapy is NOT effective for beryllium — the metal is poorly soluble and persists in tissue indefinitely

Chronic beryllium disease:

• Remove from further beryllium exposure — though evidence that removal alone improves outcomes is limited; disease frequently progresses even after exposure ceases
• Corticosteroids — first-line pharmacotherapy:
  • Prednisone 20–40 mg daily or every other day for 3–6 months
  • Taper guided by symptoms, PFTs, and gas exchange
  • Long-term low-dose maintenance may be necessary
• Steroid-sparing agents for patients who fail or cannot tolerate corticosteroids:
  • Methotrexate (7.5 mg/week with folic acid; monitor CBC and LFTs every 8–12 weeks)
  • Azathioprine
  • Mycophenolate mofetil
  • Infliximab (under investigation)
• Supplemental O2 to maintain SpO2 ≥90%
• Pulmonary rehabilitation
• Lung transplantation for end-stage disease (limited experience; effectiveness uncertain)
• Beryllium sensitization without CBD: No treatment required; remove from exposure; periodic monitoring with PFTs, CXR, and BeLPT for progression to CBD
• Lifelong follow-up: Serial PFTs, ABGs, CXR; patients with CBD require ongoing monitoring even if asymptomatic

Reporting and occupational considerations:

• CBD is a compensable occupational illness — document exposure history thoroughly
• Federal workers exposed at DOE facilities may be eligible for compensation under the Energy Employees Occupational Illness Compensation Program
• Report to OSHA / state occupational health authorities as appropriate
• Beryllium is a known human carcinogen — patients with CBD should be counseled about increased lung cancer risk and offered appropriate cancer surveillance

Disposition

• Admit:
  • Acute beryllium disease with significant hypoxemia, respiratory distress, or chemical pneumonitis
  • Suspected ARDS from acute inhalation
  • New presentation of CBD with respiratory failure or significant hypoxemia
  • Severe exacerbation of known CBD
• Discharge with close follow-up:
  • Stable known CBD patient with mild symptoms at baseline
  • Suspected CBD in a stable patient — arrange:
    • Occupational medicine or pulmonology referral (ideally to a center with beryllium disease expertise) within 1–2 weeks
    • BeLPT testing (requires specialized lab — coordinate with occupational medicine)
    • HRCT if not performed
    • PFTs with DLCO
  • Minor skin exposure — irrigate thoroughly; refer to occupational medicine for BeLPT screening
• Discharge counseling:
  • Return for worsening dyspnea, fever, or new respiratory symptoms
  • Avoid further beryllium exposure — discuss with employer and occupational health
  • If diagnosed with sarcoidosis previously and any beryllium exposure history exists, inform referring physician to order BeLPT
  • Smoking cessation (beryllium is a lung carcinogen; smoking compounds risk)

See Also

• Sarcoidosis
• Pneumoconiosis
• Silicosis
• Asbestosis
• Toxic inhalation
• Hypersensitivity pneumonitis
• ARDS
• Heavy metal toxicity

External Links

• Berylliosis — StatPearls
• ATS Statement: Diagnosis and Management of Beryllium Sensitivity and CBD (2014)
• Beryllium Health Effects — OSHA
• Beryllium Disease — Merck Manual Professional
• Berylliosis — NORD
• Toxicological Profile for Beryllium — ATSDR